Welcome Visitor Wednesday, December 18, 2024
 Access
  About Us
  Send Editor NEWS
  Most Pop Stories
  Tweeting
  Ethics & Standards
  Login
  Account
 Advertisement
 Nashville Life
  The Parks
  Visit Nashville
Franklin-linked Nodality nets $15.5MM from VC funds
By Milt Capps Updated 9:45 p.m. March 24, 2009
Published March 22, 2010
Comment Print

CEO David Parkinson, M.D.

San Francisco-based Nodality Inc., a biotechnology company with a key research and development laboratory in Franklin, today announced raising $15.5 million from venture capital investors.

Nodality CEO David Parkinson, M.D., told VNC today the company, which is focused on the development of next generation personalized medicine tests in cancer and autoimmune disease, now has a dozen staff in Franklin, with nearly 40 in the Bay Area.  A year ago, Nodality had seven persons here.

Parkinson was in Nashville last week, briefing his Franklin staff on the significance of the new investment, and on continuing plans to advance personalized medicine and accelerate drug development. 

With an eye toward the long haul, Parkinson told VNC this morning that, "you don't raise more money than you need" for each phase of a biotechnology firm's development, but raising capital will surely be a continual process for Nodality, far into the future.

Nodality said in a release the round was led by Pfizer Ventures, the venture capital arm of Pfizer Inc., which had previously invested in Nodality, with participation also by Laboratory Corporation of America Holdings; Kleiner Perkins Caufield & Byers; TPG Biotechnology; and, Maverick Capital.

Nodality also said the fresh capital will be used "to support commercial activities associated with the company's launch of its first test in acute myelogenous leukemia, as well as to advance ongoing and new research and development programs in other hematologic malignancies, autoimmune diseases, and solid tumors."

Parkinson has previously explained that Nodality is essentially "surrounding" technology licensed from Stanford University with standards and bioinformatics technology, which enables professionals to manage and analyze huge amounts of data flowing from analyses of cancer-cell signatures and behavior under variable treatment conditions.  The Franklin facility's mission is to support commercialization of Nodality offerings.

Much of Nodality's work, thus far, has centered on the needs of patients with acute myeloblastic leukemia (AML). The company has been focusing on development of tests to predict, according to the Nodality website, whether or not "a particular patient is likely to respond to conventional AML treatment, or should be offered alternative treatment approaches."

As previously reported by VNC, Nodality's operation here is led by executives who had previously been with other Middle Tennessee laboratories, including Cytometry Associates and Esoterix Laboratory Services. ♦

               
 Related Articles
Lead Capital Partners advances on $125MM LCP II goal for healthcare deals
Healthtech: VanderbiltHealth said joining Aegis Ventures Digital Consortium
BioTN Life Science Venture Program now led by Karrie Dudek PhD
Virtuous Cycles: Native local VC Rockmont Partners leads Lab Logs' Series A
VUMC Brock Center GM to forge R&D ties for pharma, digital transformation
Nashville execs join board of Greater Nashville Venture Capital Association
Venture Notes - March 21, 2024
Bartholomew, Fox, Futch file for $50MM Rockmont GrowthTech Fund I
Brandon Bruce's SEC filing signals Market Square Ventures Fund I on horizon
TN's Techstars IoF's Brandon Bruce advises seedcos hit pipeline by Nov. 29
Greater Nashville Venture Capital Association advances toward kickoff
Vanderbilt IP licensed to IPO-prospect Neumora might earn VU millions
VC Caduceus Capital Partners advances early-stage digital health fund
Innova Memphis's $75MM farmtech raise advances to first-close at $40MM
Year-old Nashville-Seattle platform startup Goodship raised at least $7.4M
FINTOP CEO: SV Bank vibrations are 'wake-up call' for venture-sector actors
TN ECD-Launch Tennessee may be one step away from $117MM SSBCI grant
Chattanooga's Brickyard VC's startup 'insulator' eyes $20MM Fund I
TN ECD, LaunchTN, allies await $117M SSBCI impact-funding call
CivicEye's $12.4MM A-round fuels US growth and team-building
Kickoff: VentureSouth Chattanooga investor forum possible model for Nashville, Memphis, Knoxville
SaaS: ESG Impact exits beta, seeks capital, opts for VU Wond'ry Founder
Memphis's ESO Fund files for $150MM Fund V to back venture option moves
Whitney unmasks Jumpstart Nova VC focused on Black-led HC companies
Venture Notes - November 30, 2021 - Healthtech + Wellness
Updated: Frist Cressey Ventures ups to $300MM Fund III fundraising target
Venture Notes - July 14, 2021
Eyeing $65M SSBCI funds, TN-ECD surveys biz, entrepreneurs, DBE execs
Venture Notes - June 18, 2021
CEO confirms Meharry MMC VC partnerships with Ambitna, ReCoVer Health
RoundingWell capraise decision ahead for workflow orchestration platform
Rick Kushel: FINTOP Capital a disciplined investor amid Fintech surge
Jumpstart Health principals file for $30MM Jumpstart Nova Fund I raise
Relevance Ventures seeks 'first-call' from Technology entrepreneurs
Decode Health CEO widens view of COVID19 impact, as projections play-out
Venture Notes - December 18, 2020
Heritage Group affiliates report $315 Million Fund III progress
Whitney to lead Jumpstart fund investing in Black-owned Health startups
Exec launches Rocket Propulsion Fund via AngelList rolling-funds platform
Rocket Propulsion Fund Universe
Venture Notes - Sept. 21, 2020
Tennessee artificial-intelligence center among Presidential advisors' ideas
Harpeth Venture Advisors signals 1st close of $27.5M Opportunity Fund
TCRS CIO Brakebill provides update on PE investment, other programs
Venture Notes -- April 13, 2020
Cofounders: Startup ObjectiveGI is ramping-up ahead of Series B raise
Exploring an Alt-scenario for Bill Frist's filings for $40MM RSV QOZB LTSS
LifeScienceTN report bolsters case for more 'intentional' industry strategy
Knoxville's EDP Biotech eyes $5MM Series A, atop $17.5MM raised
Lee Molette eyes new fund for minority- and women-owned businesses
Share:
Tags: biotechnology, Cytometry Associates, David Parkinson, Kleiner Perkins Caufield & Byers, Laboratory Corporation of America Holdings, life sciences, Nodality, Pfizer, Pfizer Ventures, pharmaceuticals, TPG Biotechnology and Maverick Capital, venture capital
 @MILTCAPPS


 

Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: